Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A sterile, non-pyrogenic **peritoneal dialysis solution** containing **calcium chloride, sodium lactate, magnesium chloride, sodium chloride, and dextrose**. It has been developed and marketed by **Baxter** in products such as **DIANEAL Low Calcium** and **DELFLEX** for **intraperitoneal** use in patients with **acute or chronic renal failure** and **chronic kidney failure** requiring peritoneal dialysis. The product is a **multi-ingredient electrolyte and carbohydrate formulation** rather than a targeted molecular therapeutic: **dextrose** creates an osmotic gradient that promotes ultrafiltration and removal of waste solutes across the peritoneal membrane, while the electrolyte components and lactate buffer help maintain fluid, acid-base, and electrolyte balance during dialysis. It is an approved pharmaceutical dialysis solution, not a biologic, and its therapeutic effect derives from restoration and manipulation of physiologic fluid composition rather than binding to a single specific molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium chloride + sodium lactate + magnesium chloride + sodium chloride + dextrose.